• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Why are there so many reps and still so many diabetes managers in one territory









Yes we have too many reps - but now they are now going to tell us how many samples we should leave... More attention to number of target calls. This is just micro management and it will fail.

Worst managment team ever.
 








Yes we have too many reps - but now they are now going to tell us how many samples we should leave... More attention to number of target calls. This is just micro management and it will fail.

Worst managment team ever.

This sample thing is the dumbest issue ever. I realize they're trying to micromanage to best utilize resources and pay their tech people. Do these idiots ever go to a dr office and figure out samples are all kept together in a room or two for ALL drs to use? It's not like they're so precious they put them in their coat jacket pocket to preciously dole out. This is just a friggin game to get the right signature with the right number of samples. I hope these stupid idiots read this.

H*ll, even if you track and put the right numbers of samples with the right signature, they all go into a mutually utilized sample room/closet/bin. Nice work jackasses. This is just meaningless work and a huge waste of time to keep track of this.
 




This new deal clears the way for another realignment. Districts and regions will be reduced in size and one diabetes manager will be responsible for a diabetes district. So instead of having 4 managers for DS1,2,3, and 4, we will likely have just two. One manger will manage DS1, 2, and 3 DSS's in a given area. We will still have a separate DS4 managing contract reps. A district will be made up of 3 territories and 9 reps from DS1, 2, and 3. Specialty will remain separate. Regions sizes will also be reduced and one CBD will manage DS1, DS2, and DS3 DBM's. This will happen mid year 2014 or perhaps year end due to not wanting another big disruption during launch of Bydureon pen and Dapa. This realignment will not effect territories and rep to doctor relationship.